Ensign Peak Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Ensign Peak Advisors’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-10,811	Closed	-$581K	–	2019
2022 Q3	$581K	Hold	10,811	–	–	﹤0.01%	1376
2022 Q2	$602K	Hold	10,811	–	–	﹤0.01%	1365
2022 Q1	$759K	Hold	10,811	–	–	﹤0.01%	1356
2021 Q4	$1.04M	Sell	10,811 -14,250	-57%	-$1.32M	﹤0.01%	1258
2021 Q3	$2.18M	Hold	25,061	–	–	﹤0.01%	1073
2021 Q2	$2.05M	Hold	25,061	–	–	﹤0.01%	1116
2021 Q1	$2.38M	Hold	25,061	–	–	0.01%	1020
2020 Q4	$1.55M	Sell	25,061 -1,924	-7%	-$110K	﹤0.01%	1201
2020 Q3	$1.6M	Sell	26,985 -30,269	-53%	-$2.07M	﹤0.01%	1093
2020 Q2	$4M	Buy	57,254 +30,269	+112%	+$1.92M	0.01%	677
2020 Q1	$1.22M	Hold	26,985	–	–	﹤0.01%	1080
2019 Q4	$1.76M	Buy	+26,985	New	+$1.8M	﹤0.01%	1112

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ensign Peak Advisors's LGND Position: Q4 2022 in Review

Ensign Peak Advisors sold out of Ligand Pharmaceuticals (LGND) in Q4 2022, closing a stake of 10,811 shares — an estimated $581K sold.

Ensign Peak Advisors first reported a position in LGND in Q4 2019 and held it in 12 quarters. The position peaked at $4M in Q2 2020. 198 funds tracked by Wall St. Rank hold LGND as of Q4 2022.

Ensign Peak Advisors reported no remaining Ligand Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Ensign Peak Advisors sold 10,811 Ligand Pharmaceuticals shares in Q4 2022, an estimated $581K.
Ensign Peak Advisors first reported a position in Ligand Pharmaceuticals in Q4 2019 and held it in 12 quarters.
Ensign Peak Advisors's Ligand Pharmaceuticals position peaked at $4M in Q2 2020.
198 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.